INOVIO's Announces Peer-reviewed Data From A Retrospective Study Investigating The Long-Term Clinical And Safety Response Of Patients Treated With INO-3107 Were Published Online In The Laryngoscope; INO-3107 Shows Sustained Improvement In RRP Patients, Cutting Surgeries By Over 75% In Year 2

Author: Benzinga Newsdesk | August 11, 2025 08:09am

• Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete Response (CR) rate improved to 50% for Year 2 from 28% for Year 1
• Mean number of surgeries patients needed to control their RRP continued to drop from 4.1 surgeries per year prior to receiving INO-3107 to 1.7 for Year 1 to 0.9 for Year 2
• Partial data into the third 12-month period (Year 3 - median follow up 2.8 years following initial treatment) continued the trend of improvement and a reduced number of surgeries

PLYMOUTH MEETING, Pa., Aug. 11, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that peer-reviewed data from a retrospective study investigating the long-term clinical and safety response of patients treated with INO-3107 were published online in The Laryngoscope under the title "DNA Immunotherapy (INO-3107) Results in Long-term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)."  The data demonstrate that a majority of patients experienced continued improvement, as measured by the number of surgical procedures needed after treatment with INO-3107, beyond the initial 12-month study period of the previously published Phase 1/2 trial. 

Posted In: INO